Literature DB >> 2781554

2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced porphyria in genetically inbred mice: partial antagonism and mechanistic studies.

C Yao1, S Safe.   

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) (233 nmol/kg) causes a significant increase of hepatic uroporphyrin, heptacarboxyporphyrin, and total porphyrins in female C57BL/6 mice, ovariectomized C57BL/6 mice, male C57BL/10 mice, and male C57BL/6 mice 3 weeks after treatment. In contrast, 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) was inactive at a dose of 750 mumol/kg. Cotreatment of the mice with TCDD (233 mol/kg) plus MCDF (750 mumol/kg) resulted in partial antagonism of TCDD-induced hepatic porphyrin accumulation only in the female mice. Parallel studies in female C57BL/6 mice showed that the TCDD-induced porphyria was accompanied by the induction of hepatic microsomal aryl hydrocarbon hydroxylase (AHH) and ethoxyresorufin O-deethylase (EROD) activities and the depression of uroporphyrinogen decarboxylase (UROD). MCDF (750 mumol/kg) did not significantly affect these enzymes. In the cotreatment studies (MCDF plus TCDD), MCDF partially antagonized TCDD-induced hepatic porphyrin accumulation but did not affect the levels of hepatic AHH, EROD, or UROD. These results indicate that other factors, in addition to the induction of cytochrome P450-dependent monooxygenases and depressed UROD activity, are important in TCDD-induced porphyria in C57BL/6 female mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2781554     DOI: 10.1016/0041-008x(89)90307-4

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

1.  Comparisons of differential gene expression elicited by TCDD, PCB126, βNF, or ICZ in mouse hepatoma Hepa1c1c7 cells and C57BL/6 mouse liver.

Authors:  Rance Nault; Agnes L Forgacs; Edward Dere; Timothy R Zacharewski
Journal:  Toxicol Lett       Date:  2013-08-29       Impact factor: 4.372

2.  Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Authors:  Shu Zhang; KyoungHyun Kim; Un Ho Jin; Catherine Pfent; Huojun Cao; Brad Amendt; Xinyi Liu; Heather Wilson-Robles; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2011-10-27       Impact factor: 6.261

3.  Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.

Authors:  Un-Ho Jin; Syng-ook Lee; Stephen Safe
Journal:  J Pharmacol Exp Ther       Date:  2012-08-09       Impact factor: 4.030

4.  Altered hepatic iron distribution and release in rats after exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Authors:  Z Z Wahba; W J Murray; S J Stohs
Journal:  Bull Environ Contam Toxicol       Date:  1990-09       Impact factor: 2.151

5.  The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

Authors:  Shu Zhang; Ping Lei; Xinyi Liu; Xiangrong Li; Kelcey Walker; Leela Kotha; Craig Rowlands; Stephen Safe
Journal:  Endocr Relat Cancer       Date:  2009-05-15       Impact factor: 5.678

Review 6.  Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells.

Authors:  S Safe; M Wormke; I Samudio
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

7.  Porphyrin studies in TCDD-exposed workers.

Authors:  D Jung; J Konietzko; G Reill-Konietzko; A Muttray; H J Zimmermann-Hölz; M Doss; H Beck; L Edler; A Kopp-Schneider
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

Review 8.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

9.  The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis.

Authors:  Un-Ho Jin; Syng-Ook Lee; Catherine Pfent; Stephen Safe
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.